<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Assessing the Levels of L-Carnitine and Total Antioxidant Capacity in Adults With Newly Diagnosed and Long-Standing Type 2 Diabetes</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Millad</forename><surname>Ramazani Msc</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Clinical Biochemistry</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution">Babol University of Medical Sciences</orgName>
								<address>
									<settlement>Babol</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="laboratory">Student Research Committee</orgName>
								<orgName type="institution">Babol University of Medical Sciences</orgName>
								<address>
									<settlement>Babol</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">;</forename><surname>Durdi Qujeq</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Clinical Biochemistry</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution">Babol University of Medical Sciences</orgName>
								<address>
									<settlement>Babol</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="laboratory">Cellular and Molecular Biology Research Center</orgName>
								<orgName type="institution" key="instit1">Health Research Institute</orgName>
								<orgName type="institution" key="instit2">Babol University of Medical Sciences</orgName>
								<address>
									<settlement>Babol</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="laboratory">Cancer Research Center</orgName>
								<orgName type="institution" key="instit1">Health Research Institute</orgName>
								<orgName type="institution" key="instit2">Babol University of Medical Sciences</orgName>
								<address>
									<settlement>Babol</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Zoleika</forename><surname>Moazezi</surname></persName>
							<affiliation key="aff3">
								<orgName type="laboratory">Cancer Research Center</orgName>
								<orgName type="institution" key="instit1">Health Research Institute</orgName>
								<orgName type="institution" key="instit2">Babol University of Medical Sciences</orgName>
								<address>
									<settlement>Babol</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution" key="instit1">Ayatollah Rouhhani Hospital</orgName>
								<orgName type="institution" key="instit2">Babol University of Medical Sciences</orgName>
								<address>
									<settlement>Babol</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>PhD</roleName><forename type="first">Durdi</forename><surname>Qujeq</surname></persName>
							<email>d.qujeq@mubabol.ac.ir</email>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Department of Clinical Biochemistry</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution">Babol University of Medical Sciences</orgName>
								<address>
									<addrLine>Ganjafrooze Street</addrLine>
									<settlement>Babol</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Assessing the Levels of L-Carnitine and Total Antioxidant Capacity in Adults With Newly Diagnosed and Long-Standing Type 2 Diabetes</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">09ED0AF4800AE9D0F2C2A31FEA2038CF</idno>
					<idno type="DOI">10.1016/j.jcjd.2018.03.009</idno>
					<note type="submission">Received 20 June 2017 Accepted 19 March 2018</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:40+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>cholesterol fasting plasma glucose L-carnitine total antioxidant capacity triglycerides</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>This study is a correlative study that examined the potential of reduced levels of L-carnitine to add to the pathophysiology of type 2 diabetes.</s></p><p><s>• Multivariate logistic regression analysis showed that L-carnitine was significantly positively associated with total antioxidant capacity and negatively correlated with fasting blood sugar, triglycerides and body mass indexes in patients with type 2 diabetes.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Mots clés : cholestérol glucose plasmatique à jeun L-carnitine capacité antioxydante totale triglycérides r é s u m é Objectifs : Cette étude est essentiellement une étude de corrélations qui examine le potentiel des niveaux réduits de L-carnitine (LC) en association avec la physiopathologie du diabète de type 2. Le but de l'étude était d'évaluer les niveaux de LC, la capacité antioxydante totale (TAOC), la glycémie à jeun (FBS), les triglycérides et le cholestérol chez des personnes atteintes d'un diabète de type 2 de longue date ou récemment diagnostiqué, et chez des témoins sains.</s><s>Méthodes : L'étude a été réalisée chez 90 sujets adultes, dont 30 avec un diabète nouvellement diagnostiqué, 30 avec un diabète de type 2 de longue date et 30 contrôles sains.</s><s>Des échantillons de plasma ont été utilisés pour mesurer les paramètres biochimiques.</s><s>Résultats : Dans cette étude, les deux groupes (diabète de type 2 nouvellement diagnostiqué et diabète de type 2 de longue date) présentaient des caractéristiques de base significativement différentes, telles que l'âge, la taille, le poids, l'indice de masse corporelle, le FBS, le cholestérol et les triglycérides.</s><s>Les taux plasmatiques de LC chez les patients atteints de diabète de type 2 nouvellement diagnostiqué et de longue date étaient significativement plus faibles que chez les témoins en bonne santé (p&lt;0,001).</s><s>En outre, le niveau moyen de TAOC plasmatique chez les patients atteints de diabète de type 2 nouvellement diagnostiqué et de longue date était légèrement inférieur à celui des témoins sains.</s><s>Néanmoins, les niveaux</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>It is widely accepted that type 2 diabetes is 1 of the most important health problems in the modern world, and it requires new diagnostic tools to assess early detection <ref type="bibr" target="#b0">(1)</ref>.</s><s>Researchers have reported that L-carnitine (LC) exhibits significant Ca 2+ chelating activity.</s><s>LC can affect the calcium-dependent biologic systems because Ca 2+ is important in the biochemical and physiological processes of living cells <ref type="bibr" target="#b1">(2)</ref>.</s><s>Much evidence has been accumulated in recent years that indicates that LC seems to improve glucose metabolism and, thus, has been recommended as a useful therapeutic agent for treating patients with type 2 diabetes (3).</s><s>Previous studies have shown that plasma LC levels are reduced in patients with type 2 diabetes (3).</s><s>In another study, it was demonstrated that LC plays a role in the increase of fasting plasma glucose levels, and it increases triglyceride concentrations in patients with type 2 diabetes (3).</s><s>It has been said that diabetes mellitus is a global metabolic disorder described by hyperglycemia, dyslipidemia and dysfunction of protein metabolism (4).</s><s>Supplementation with LC improves glycemic control in people with type 2 diabetes <ref type="bibr" target="#b4">(5)</ref>.</s><s>LC is an endogenous metabolite and an exogenous nutrient that plays a pivotal role in lipid metabolism.</s><s>Plasma levels of carnitine are reduced in type 2 diabetes.</s><s>The administration of LC in type 2 diabetes mellitus is associated with an improvement in glycemia and plasma lipid levels <ref type="bibr" target="#b5">(6)</ref>.</s><s>Administration of LC causes a decrease in glucose concentration levels but an increase in triglycerides <ref type="bibr" target="#b6">(7)</ref>.</s><s>Higher LC (3-hydroxy-4-Ntrimethylammonio-butanoate) concentrations do not prevent late complications of diabetes in patients with type 1 and type 2 diabetes <ref type="bibr" target="#b7">(8)</ref>.</s></p><p><s>Orlistat plus LC showed better improvement in body weight and glycemic and lipid profiles than orlistat alone.</s><s>Furthermore, a faster and better improvement in inflammatory parameters was observed with orlistat plus LC as compared to orlistat only <ref type="bibr" target="#b8">(9)</ref>.</s><s>LC affects the regulation of cellular respiration as well as the activity of enzymes that defend against oxidative damage and prevent oxidative stress.</s><s>LC plays an important role as an antioxidant <ref type="bibr" target="#b9">(10)</ref>.</s><s>Moreover, recent evidence has indicated that oxidative stress plays a major role in the pathogenesis of diabetes mellitus <ref type="bibr" target="#b10">(11)</ref>.</s><s>Increasing evidence shows that hyperglycemia and oxidative stress play important roles in elevating the complications of diabetes, possibly by utilizing their effects through hyperglycemia-induced reactive oxygen species and overproduction by the mitochondrial electron-transport system.</s><s>In chronic diabetes mellitus, high plasma levels of glucose and the production of reactive oxygen species at this stage damage the islet cells through oxidative stress <ref type="bibr" target="#b11">(12,</ref><ref type="bibr" target="#b12">13)</ref>.</s><s>The main aims of this study were 1) to investigate changes in the biochemical factors in patients with newly diagnosed and long-standing type 2 diabetes; and 2) to analyze the association of LC levels with body mass index (BMI), fasting blood sugar (FBS), cholesterol (Chol), triglycerides (TG) and total antioxidant capacity (TAOC) levels that were involved in both newly diagnosed and long-standing type 2 diabetes.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>In this case-controlled study, plasma LC, TAOC, FBS, TG, Chol, weight (kg), height (m) and BMI (calculated as weight divided by height squared) were determined.</s><s>To inspect the relationship between LC and TAOC in patients with diabetes, 3 groups were recruited.</s><s>Group 1 included 30 patients with long-standing type 2 diabetes (9 male, 21 female) and with complications related to type 2 diabetes for at least 2 years at the time of diagnosis.</s><s>Group 2 included 30 newly diagnosed patients (7 male, 23 female).</s><s>Group 3 included 30 healthy controls (9 male, 21 female).</s><s>The groups were between 25 and 75 years of age.</s><s>The patients were from Iran and were diagnosed according to the principles of the American Diabetes Association.</s></p><p><s>The inclusion criteria were as follows.</s><s>In patients newly diagnosed with diabetes, FBS levels &gt;125 mg/dL and BMIs &gt;25 kg/m 2 were established.</s><s>The duration of diabetes in subjects with long-standing diabetes was 2 years at the time of diagnosis and they had longterm complications resulting from type 2 diabetes.</s><s>The diabetes statuses in each group were diagnosed by an expert endocrinologist.</s><s>The exclusion criteria were taking any drug or suffering from other diseases as well.</s><s>Informed consent was obtained from all the patients for subsequent use of their blood samples.</s><s>This study was cleared by the University Ethics Review Board for human studies (p/J/30/ 5262,93/12/23), and all the patients signed informed consents.</s><s>The experiment's protocols were approved by the Babol University of Medical Sciences (#2637).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Laboratory assessment</head><p><s>Blood samples were obtained from all subjects and were collected in acid-washed pipes.</s><s>Plasma was obtained from these blood samples by adding 1 mg/mL Na2-EDTA.</s><s>The samples were centrifuged at 3000g for 5 min.</s><s>Immediately after this, the plasma samples were stored at −20 o C for 4 weeks and then moved to −80 o C until use.</s><s>FBS levels were measured using the glucose-oxidation method <ref type="bibr" target="#b13">(14)</ref>, and TG and Chol levels <ref type="bibr" target="#b14">(15)</ref> were measured by the enzymatic method (Pars Azmoon Sanat Pooya, Tehran, Iran).</s><s>LC and TAOC concentrations were measured using the sandwich enzymelinked immunosorbent assay (ELISA) method, following the manufacturer's instructions (Bioassay Technology Laboratory, Shanghai, China).</s><s>These assays were validated using other complementary methodology to confirm the outcomes determined by the ELISA assay.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>The data were expressed as the mean ± standard deviation.</s><s>All data are presented as adjusted predictive values based on a linear regression model, using age and BMI as independent variables.</s><s>The endpoint level for statistical significance was set at p&lt;0.05, and the analysis of variance (ANOVA) test was used to define differences among dependent groups.</s><s>The strength of association between pairs of variables was assessed using the Pearson correlation coefficient.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Based on the results presented in Table <ref type="table" target="#tab_0">1</ref>, we can conclude that subjects with long-standing type 2 diabetes had higher levels of some characteristics such as age, as compared to the newly diagnosed patients with diabetes.</s><s>BMI levels were higher but only in patients with long-standing diabetes.</s><s>Nonetheless, those with long-standing type 2 diabetes had lower levels of such characteristics as height.</s><s>Laboratory parameters, such as FBS, Chol and TG levels, were higher in those with long-standing type 2 diabetes than in those with newly diagnosed type 2 diabetes and healthy controls.</s></p><p><s>Table <ref type="table" target="#tab_1">2</ref> indicates that the LC levels were significantly different across all the groups (p&lt;0.001).</s><s>Plasma LC levels in patients with newly diagnosed and long-standing type 2 diabetes were significantly lower than those in healthy controls (p&lt;0.001).</s><s>Also, the mean plasma TAOC levels in the patients with newly diagnosed and longstanding type 2 diabetes were slightly lower than those of the healthy controls.</s><s>Nevertheless, TAOC levels were not significantly different among the groups (p=0.87).</s></p><p><s>In addition, the correlation between LC levels and BMI, FBS, Chol, TG and TAOC levels in patients with newly diagnosed and longstanding type 2 diabetes was analyzed using correlation curve analysis (Figure <ref type="figure" target="#fig_0">1</ref>).</s><s>Plasma LC levels were significantly positive as compared to plasma TAOC levels (r=0.516).</s><s>Hence, an increase in the LC level is associated with an increase in the TAOC level.</s><s>However, there is a negative correlation between LC level and FBS (r=-0.387),</s><s>TG (-0.159) and BMI level (r=-0.068).</s><s>This means that a decrease in the LC level is associated with an increase in FBS, TG and BMI.</s><s>(Supplementary Figure <ref type="figure" target="#fig_0">1</ref>)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>The most important findings of this research were the effects of reduced LC levels in the patients with long-standing type 2  diabetes; the effects were greater than those in the newly diagnosed patients.</s><s>The amount of FBS, Chol and TG contents were higher in the patients with long-standing type 2 diabetes than in the newly diagnosed patients.</s><s>Our results show that with lower LC levels, the chance of getting diabetes increases more in patients with longstanding type 2 diabetes than in patients with newly diagnosed diabetes.</s><s>This effect may be due to the accumulation of various metabolites in the mitochondria or may be related to insulin resistance.</s><s>It is well known that LC is necessary for the transfer of longchain fatty acids into the mitochondrial matrix and for the efflux of acyl groups out of the mitochondria.</s><s>The accumulation of intracellular lipid derivatives within the mitochondria plays a major role in the development of insulin resistance.</s><s>It is important to emphasize that insulin resistance is a key element in the pathogenesis of newly diagnosed and long-standing type 2 diabetes.</s><s>Because of this effect, the role of LC has gained attention as a tool for the treatment of insulin resistance in patients with type 2 diabetes.</s><s>The findings of this study indicate that a decrease in the LC levels in patients with newly diagnosed and long-standing type 2 diabetes has a negative effect on plasma lipid levels.</s><s>A significant negative correlation was observed between the levels of LC and TG (r=-0.159).</s></p><p><s>An important finding in this study was that LC levels in patients with long-term and newly diagnosed type 2 diabetes were lower compared to the healthy control group.</s><s>This result is in accordance with the findings of other studies <ref type="bibr" target="#b6">(7)</ref>.</s><s>Because of the role played by LC in lipid and carbohydrate metabolism, decreases in the LC level could cause complications for patients with type 2 diabetes.</s><s>This study also demonstrated that Chol and TG levels in patients with long-standing type 2 diabetes are considerably higher than in patients with newly diagnosed type 2 diabetes and the healthy control group.</s><s>These results suggest that LC levels have a reverse relationship with Chol and TG levels.</s><s>Such findings correlate with other results, which claim that LC deficiency causes abnormalities in lipid metabolism and may cause dyslipidemia ( <ref type="formula">16</ref>).</s><s>An explanation could be related to the fact that a reduction in fatty acid transport inside the mitochondria following the reduction of LC levels results in the cytosolic accumulation of TG and Chol.</s><s>The results of this study are in accordance with other research <ref type="bibr" target="#b6">(7,</ref><ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b17">18)</ref>.</s><s>Conversely, the study by Derosa et al of patients with diabetes and that of Huang et al of patients undergoing hemodialysis showed that LC supplementation did not have any significant effect on serum total Chol or TG levels <ref type="bibr" target="#b15">(16,</ref><ref type="bibr" target="#b18">19)</ref>.</s></p><p><s>This study showed that FBS levels in patients with newly diagnosed and long-standing type 2 diabetes were higher than those in the healthy controls.</s><s>On the other hand, LC had a negative correlation with FBS levels (r=-0.387).</s><s>The explanation for this could be related to the role of LC.</s><s>First, low LC levels decrease the level of cytoplasmic acetyl-CoA due to an inhibition of pyruvate dehydrogenase activity.</s><s>Second, there is a decrease in metabolism due to the effect of LC, which plays a regulatory role in the synthesis and degradation of important glycolytic and gluconeogenic enzymes related to carbohydrate metabolism.</s><s>The roles of LC suggest that decreased LC levels cause a rise in the FBS levels and increase the risk for diabetes in patients with diabetes because it causes a decrease in acetyl-CoA and diminishes glucose-induced insulin secretion.</s><s>This observation correlates with other findings: low LC levels affect the metabolism of glucose <ref type="bibr" target="#b19">(20,</ref><ref type="bibr" target="#b20">21)</ref>.</s><s>The patients in the Mingrone study showed that in type 2 diabetes, LC increases glucose uptake and regulates the synthesis of glycolytic and gluconeogenic enzymes <ref type="bibr" target="#b21">(22)</ref>.</s></p><p><s>This study indicated that TOAC concentration in patients with newly diagnosed and long-standing type 2 diabetes was significantly lower than its mean concentration level in the controls.</s><s>These findings are in accordance with the results of other studies <ref type="bibr" target="#b22">(23)</ref>.</s><s>These results could be related to the fact that reactive oxygen species are more numerous in patients with diabetes <ref type="bibr" target="#b11">(12)</ref>.</s><s>However, in this issue, there was no significant difference between patients with newly diagnosed diabetes and long-standing type 2 diabetes compared with the controls.</s><s>On the contrary, Savu et al showed that in patients with diabetes, antioxidant levels decrease more than in healthy subjects <ref type="bibr" target="#b11">(12)</ref>.</s><s>This might be due to the ages of the subjects.</s><s>As age increases, oxidative damage has an inverse effect on total body antioxidants.</s></p><p><s>TAOC levels had a positive relationship with LC levels according to their significant correlations.</s><s>LC averts oxidative stress and normalizes the activity of enzymes involved in the body's defense system.</s><s>In contrast to oxidative damage, it shows that LC has an effective antioxidant activity, including reducing the power of superoxide anion radical scavenging, hydrogen peroxide scavenging and metal-chelating activities <ref type="bibr" target="#b10">(11)</ref>.</s></p><p><s>In addition, the association of LC with other components involved in both newly diagnosed and long-standing type 2 diabetes, such as BMI, FBS, Chol, TG and TAOC levels, were analyzed by correlation curve analysis.</s><s>It is suggested that the association of LC levels with TAOC levels might be due to the high prevalence of free radicals in these patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>In conclusion, multivariate logistic regression analysis showed that LC had a significant positive association with TAOC, while it had a negative correlation with FBS, TG and BMI levels in the patients with newly diagnosed and long-standing type 2 diabetes.</s><s>LC levels were found to be lower in patients with newly diagnosed and longstanding type 2 diabetes as compared to the healthy controls.</s><s>Patients with long-standing type 2 diabetes had worse metabolic profiles when compared with the healthy controls.</s><s>According to our results the most effective of reduced LC levels on the metabolic profiles of patients with long-standing type 2 diabetes, setting the LC content so as to prevent diabetes through the use of effective drugs or nutrition therapy containing LC can be useful in controlling diabetes.</s><s>These results might be used in the prevention of diabetes or the improvement of complications of diabetes.</s><s>However, further studies are needed to elucidate the mechanism in this regard, and more comprehensive investigations are being carried out in our laboratory.</s></p><p><s>This study has some limitations.</s><s>The small sample size might have led to discrepancies in the results of statistical analyses.</s><s>Nonetheless, the study is sufficient to demonstrate novel associations of LC with FBS, Chol, TG and TAOC levels in patients with newly diagnosed and long-standing type 2 diabetes.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Correlation among L-carnitine, triglycerides (TG), cholesterol (Chol), fasting blood sugar (FBS) and body mass index (BMI) in patients with type 2 diabetes.</s><s>TAOC, total antioxidant capacity.</s></p></div></figDesc><graphic coords="3,295.87,159.21,252.00,312.39" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="6,40.74,71.15,516.24,226.68" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Baseline demographic characteristics of the patients with newly diagnosed and longstanding type 2 diabetes and the healthy control group</s></p></div></figDesc><table><row><cell>Variables</cell><cell>Long-standing</cell><cell>Newly diagnosed</cell><cell>Control group</cell><cell>p value</cell></row><row><cell></cell><cell>type 2 diabetes</cell><cell>type 2 diabetes</cell><cell></cell><cell></cell></row><row><cell>Age (y)</cell><cell>58.03 (9.03)</cell><cell>49.43 (10.77)</cell><cell cols="2">43.96 (13.04) &lt;0.001</cell></row><row><cell>Height (m)</cell><cell>155 (8.42)</cell><cell>159.73 (10.56)</cell><cell>170.89 (8.51)</cell><cell>&lt;0.001</cell></row><row><cell>Weight (kg)</cell><cell>75.73 (15.56)</cell><cell>74.7 (15)</cell><cell>80.68 (9.85)</cell><cell>&lt;0.2</cell></row><row><cell>BMI (kg/m 2 )</cell><cell>31.39 (4.60)</cell><cell>29.22 (4.04)</cell><cell>27.54 (2.04)</cell><cell>0.001</cell></row><row><cell>FBS (mg/dL)</cell><cell>183.13 (42.93)</cell><cell>155.7 (82.25)</cell><cell>84.43 (5.63)</cell><cell>&lt;0.001</cell></row><row><cell>Chol (mg/dL)</cell><cell>198.6 (44.98)</cell><cell>179.9 (72.04)</cell><cell>164.5 (25.68)</cell><cell>0.027</cell></row><row><cell>TG (mg/dL)</cell><cell>187.6 (74.36)</cell><cell>174.2 (74.71)</cell><cell cols="2">117.2 (32.43) &lt;0.001</cell></row></table><note><p><s>Note: Results represent mean ± SD obtained from 3 separate experiments.</s><s>BMI, body mass index; Chol, cholesterol; FBS, fasting blood sugar; TG, triglycerides.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Laboratory parameters in patients with newly diagnosed and long-standing type 2 diabetes and healthy control groups</s></p></div></figDesc><table><row><cell>Groups/</cell><cell>Long-standing</cell><cell>Newly diagnosed</cell><cell>Control</cell><cell>p value</cell></row><row><cell>variables</cell><cell>type 2 diabetes</cell><cell>type 2 diabetes</cell><cell></cell><cell></cell></row><row><cell>LC</cell><cell>49.51 (4.82)</cell><cell>56.09 (5.09)</cell><cell>68.51 (9.40)</cell><cell>&lt;0.001</cell></row><row><cell>TAOC</cell><cell>26.23 (3.67)</cell><cell>28.68 (3.17)</cell><cell>29.84 (10.93)</cell><cell>0.87</cell></row></table><note><p><s>Note: Results represent mean ± SD obtained from 3 separate experiments.</s><s>LC, L-carnitine; TAOC, total antioxidant capacity.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">M. Ramazani et al. / Can J Diabetes 43 (2019) 46-50</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>The authors gratefully acknowledge support from Babol University of Medical Sciences (#9339512).</s><s>We are grateful to the department of Clinical Biochemistry at Babol University of Medical Sciences for analysis of biochemical parameters.</s><s>We thank Ansar Karimian for English editing.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary Material</head><p><s>To access the supplementary material accompanying this article, visit the online version of Canadian Journal of Diabetes at https:// www.canadianjournalofdiabetes.com.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p><s>This project was funded by Babol University of Medical Sciences research grant as a Master's of science thesis research grant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author Disclosures</head><p><s>Conflicts of interest: None.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author Contributions</head><p><s>All authors of this article directly participated in the planning, execution and analysis of the study.</s><s>DQ designed the study; MR, ZM and DQ conducted the research; MR analyzed the data and performed the statistical analyses; MR and DQ wrote the article; DQ takes primary responsibility for the final content.</s><s>All authors read and approved the final manuscript.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary Material</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Epidemiology of diabetes mellitus: A current review</title>
		<author>
			<persName><forename type="first">I</forename><surname>Vlad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Popa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rom J Diabetes Nutr Metab Dis</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="433" to="440" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">l-Carnitine is a calcium chelator: A reason for its useful and toxic effects in biological systems</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Banihani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bayachou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Alzoubi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Basic Clin Physiol Pharmacol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="141" to="145" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Determination of free L-carnitine levels in type II diabetic women with and without complications</title>
		<author>
			<persName><forename type="first">A</forename><surname>Poorabbas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fallah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bagdadchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="892" to="895" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a World Health Organization consultation</title>
		<author>
			<persName><forename type="first">Kgmm</forename><surname>Alberti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zimmet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diabet Med</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="539" to="553" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Role of L-carnitine and coenzyme Q10 as adjuvant therapy in patients with type 2 diabetes mellitus</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Mohammed-Jawad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Al-</forename><surname>Sabbagh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Al-Jezaeri</forename></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pharmacol Sci</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="82" to="86" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Metabolic effects of L-carnitine on type 2 diabetes mellitus: Systematic review and metaanalysis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Vidal-Casariego</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Burgos-Peláez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Martínez-Faedo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exper Clin Endocrinol Diabetes</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="234" to="238" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Effect of L-carnitine on plasma glycemic and lipidemic profile in patients with type II diabetes mellitus</title>
		<author>
			<persName><forename type="first">A</forename><surname>Rahbar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Shakerhosseini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Saadat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Taleban</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pordal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gollestan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="592" to="596" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">High L-carnitine concentrations do not prevent late diabetic complications in type 1 and 2 diabetic patients</title>
		<author>
			<persName><forename type="first">E</forename><surname>Liepinsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Skapare</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Vavers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nutr Res</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="320" to="327" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Comparison between orlistat plus L-carnitine and orlistat alone on inflammation parameters in obese diabetic patients</title>
		<author>
			<persName><forename type="first">G</forename><surname>Derosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Maffioli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ferrari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Fundam Clin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="642" to="651" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Antioxidant and antiradical activities of L-carnitine</title>
		<author>
			<persName><forename type="first">İ</forename><surname>Gülçin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Life Sci</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="803" to="811" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Association between PGC-1alpha gene polymorphisms and type 2 diabetes risk: A case-control study of an Iranian population</title>
		<author>
			<persName><forename type="first">S</forename><surname>Shokouhi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Haghani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Borji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bakhtiyari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Can J Diabetes</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="65" to="72" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Increase in total antioxidant capacity of plasma despite high levels of oxidative stress in uncomplicated type 2 diabetes mellitus</title>
		<author>
			<persName><forename type="first">O</forename><surname>Savu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ionescu-Tirgoviste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Atanasiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gaman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Papacocea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Stoian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Int Med Res</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="709" to="716" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">A review on the role of antioxidants in the management of diabetes and its complications</title>
		<author>
			<persName><forename type="first">R</forename><surname>Rahimi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nikfar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Larijani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Abdollahi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biomed Pharmacother</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="365" to="373" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Berberis fruit extract and biochemical parameters in patients with type ii diabetes</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Moazezi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Qujeq</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Jundishapur J Nat Pharm Prod</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">e13490</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Relationship of total homocysteine, cholesterol, triglyceride in the serum and diastolic blood pressure of patients with myocardial infarction</title>
		<author>
			<persName><forename type="first">D</forename><surname>Qujeq</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hossini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Salehi Omran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Iran Biomed J</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="97" to="101" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">The effect of L-carnitine on plasma lipoprotein (a) levels in hypercholesterolemic patients with type 2 diabetes mellitus</title>
		<author>
			<persName><forename type="first">G</forename><surname>Derosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Cicero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gaddi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mugellini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ciccarelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fogari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Ther</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1429" to="1439" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Improvement of myocardial function in diabetic rats after treatment with L-carnitine</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Paulson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Traxler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Metabolism</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="358" to="363" />
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Lack of effect of oral L-carnitine treatment on lipid metabolism and cardiac function in chronically diabetic rats</title>
		<author>
			<persName><forename type="first">B</forename><surname>Rodrigues</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Seccome</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Mcneill</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Can J Physiol Pharmacol</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="1601" to="1608" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Influence of L-carnitine supplementation on serum lipid profile in hemodialysis patients: A systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">H</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Blood Press Res</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="31" to="41" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Risks and benefits of carnitine supplementation in diabetes</title>
		<author>
			<persName><forename type="first">M</forename><surname>Dambrova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Liepinsh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Clin Endocrinol Diabetes</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="95" to="100" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Fenkci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Fenkci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Oztekin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Karagenc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Reprod</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1602" to="1606" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Carnitine in type 2 diabetes</title>
		<author>
			<persName><forename type="first">G</forename><surname>Mingrone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann N Y Acad Sci</title>
		<imprint>
			<biblScope unit="volume">1033</biblScope>
			<biblScope unit="page" from="99" to="107" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Increase in total antioxidant capacity of plasma despite high levels of oxidative stress in uncomplicated type 2 diabetes mellitus</title>
		<author>
			<persName><forename type="first">O</forename><surname>Savu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ionescu-Tirgovistel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Atanasiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gaman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Papacocea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Stoian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Int Med Res</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="709" to="716" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
